Polyneuron adds Graziano Seghezzi and David Mott to Board along with raising CHF22.5m Series A financing co-led by Sofinnova Partners and NEA
– SWITZERLAND, Basel – Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, today announced the closing of an oversubscribed CHF22.5 million Series A financing.…